ResourceDrug Discovery & Development
Bridging bench science with clinical development: Inotiv’s integrated science approach to de-risking small molecule drug candidates
15 Sept 2026This whitepaper explores how Inotiv combines drug metabolism, drug-drug interaction (DDI) and translational science expertise to support the development of small molecule therapeutics. Learn how integrated approaches including CYP enzyme inhibition studies, reaction phenotyping, metabolite identification, and targeted proteomics help identify potential safety risks early in development. Explore a case study involving tucatinib and CYP3A4 mechanism-based inactivation, that demonstrates how mechanistic insights can inform regulatory submissions, guide clinical development strategies, and reduce risk as drug candidates advance toward the clinic.
Resource details:
Resource type: Whitepaper
Page count: 2
Read time: 4 mins
Links
Tags
Drug DeliveryDrug Delivery refers to dosage form, route of administration, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. Drug delivery is often approached via the biopharmaceutical or small molecule drug's formulation, but it may also involve medical devices or drug-device combination products. Considerations include instrumentation, software and services. Drug MetabolismDrug metabolism is the enzymatic conversion within the body of pharmaceutical substances into other chemical compounds. The primary site for drug metabolism is the liver.